ESR1 and breast cancer: In groups stratified to include chemotherapy treated and untreated breast cancer cases, TNBC patients with high expressions of PAK1 (226507) and SIK2, ER+ patients with high expression of QSK and BRSK2, and mutant TP53 patients with high BRSK1 expression all had an improved survival correlation post chemotherapy.